People - December 2003

Dr Mark Egerton has joined the board of UK biopharmaceutical company Oxagen as chief commercial officer. Most recently he was ceo of Cyprotex, a UK-based company specialising in providing pre-clinical services to the biotech and drug industries.

Development services company Ultrafine, of Manchester in the UK, has made two key appointments. Dr Rick Dyer has been named head of chemical operations. He was previously head of chemical synthesis at Roche Discovery. Meanwhile Joseph Siple becomes the company's North American business development director. He joins the company from Chemical Synthesis Services (CSS), of Northern Ireland, where he was business development director.

Richard Lingard has been appointed as vp business development at Argenta Discovery. He will be primarily responsible for the company's European business development and will be based in Argenta's headquarters at Harlow in the UK. Lingard joins Argenta from UK-based drug discovery company Inpharmatica, where he was responsible for leading global business development for a key business line.

Inpharmatica, the selective drug discovery company, has appointed Dr Andrew Ayscough as director of chemistry and a team of seven medicinal chemists have been recruited from Millennium Pharmaceuticals. Dr Ayscough was previously director of research at British Biotech, where he was responsible for the direction of the company's medicinal chemistry programmes. Dr Edwin Moses has also been appointed as non-executive chairman. He has been a non-executive director of the company since July 2001. Sir Harry Solomon, the company's former chairman, remains as a board director. Dr Moses was previously ceo of Oxford Asymmetry International (OAI) and was responsible for its merger with EVOTEC BioSystems in 2000.

Mike Severs has joined pressure safety systems provider Elfab as sales and marketing manager. He previously held the same position at precision machine and bespoke process equipment manufacturer Express Engineering.

Friedrich Christ, senior vice president of BASF, has been appointed as chairman of the supervisory board of Axaron Bioscience. He succeeds Dr Klaus Juergen Boehm, whose mandate expired at the last general meeting.

Nastech, a US-leader in drug delivery technology, has appointed Dr Paul Johnson, as senior vp, r&d and cso.

You may also like